Page 81 - 2019年10月第30卷第19期
P. 81

基于数据挖掘分析含白芍中成药的组方规律                                                  Δ



                                                                 2
               1*
                                        1
                        1
                                                 1
                                                                         2 #
        黄远程 ,蒋凯林 ,朱朝阳 ,廖 柳 ,林煜翔 ,梁怀枫 ,李培武 ,刘凤斌 (1.广州中医药大学第一临床医学院,
                                                         1
                                1
        广州 510006;2.广州中医药大学第一附属医院脾胃病科,广州 510405)
        中图分类号 R932          文献标志码 A           文章编号 1001-0408(2019)19-2668-06
        DOI   10.6039/j.issn.1001-0408.2019.19.15
        摘   要   目的:分析含白芍中成药的组方规律,为白芍的现代临床应用及新药开发提供依据。方法:收集《中药成方制剂》和2015
        年版《中国药典》中含白芍的中成药处方,采用中医传承辅助平台V 2.5中描述性统计、关联规则分析等数据挖掘方法,统计含白芍
        中成药处方中的药材频次及其性味归经、主治疾病与证候分布、核心药材组合(设置支持度分别为 10%、20%、30%,置信度为
        0.9),并对常见的主治疾病及主治证候(设置支持度为20%、30%、40%,置信度为0.9)进行组方规律分析。结果:共统计含白芍中
        成药处方600个,涉及中药673味。含白芍中成药处方中所含中药的药性主要为温性,其次为寒性、平性;药味主要为甘味,其次为
        苦味、辛味;主要归脾、肝、心经。主治疾病165种(如月经失调、痛经、眩晕),主治证候159种(如气血两虚证、气滞血瘀证、肝肾亏
        虚证)。当支持度为30%、置信度为0.9时,含白芍中成药处方的核心药材组合20个(如甘草-白芍、当归-白芍、白芍-茯苓),药材间
        关联规则19条。当支持度为40%、置信度为0.9时,含白芍中成药治疗月经失调的核心药材有8种(如白芍、香附、当归等),治疗
        眩晕的核心药材有9种(如白芍、熟地黄、当归等),治疗气血两虚证的核心药材有9种(如白芍、白术、茯苓等),治疗气滞血瘀证的
        核心药材有10种(如白芍、木香、甘草等)。结论:本研究通过数据挖掘分析了含白芍中成药的主治病证、配伍特点和组方规律,可
        为白芍的现代临床应用和新药开发提供依据。
        关键词 白芍;数据挖掘;中医传承辅助平台V2.5;组方规律;主治疾病

        Analysis of the Formulation Regularity for Chinese Patent Medicines Containing Paeonia lactiflora Based
        on Data Mining
        HUANG Yuancheng ,JIANG Kailin ,ZHU Chaoyang ,LIAO Liu ,LIN Yuxiang ,LIANG Huaifeng ,LI Peiwu ,
                                                                  1
                                                                                                          2
                                                        1
                                                                               1
                                        1
                          1
                                                                                                1
        LIU Fengbin(1.First Clinical Medical College,Guangzhou University of TCM,Guangzhou 510006,China;2.
                    2
        Dept. of Spleen and Stomach Disease, the First Affiliated Hospital of Guangzhou University of TCM,
        Guangzhou 510405,China)
        ABSTRACT    OBJECTIVE:To analyze the formulation regularity of Chinese patent medicines containing Paeonia lactiflora,and
        to provide evidence for modern clinical application and R&D of P. lactiflora. METHODS:The formulations of Chinese patent
        medicine containing P. lactiflora were collected from Chinese Materia Medica Preparation and 2015 edition of Chinese
        Pharmacopeia. Statistical analysis was performed on the frequency of medicinal material,channel tropism,distribution of attending
        syndromes and attending diseases,core medicine combination(support degrees were set as 10% ,20% ,30% and confidence
        degree was 0.9) by using data mining methods such as descriptive statistics and association rule analysis in TCM Inheritance
        System V 2.5;the formulation regularity of common attending syndromes and attending diseases (support degrees were set as
        20%,30%,40% and confidence degree was 0.9)was analyzed. RESULTS:A total of 600 Chinese patent medicine formulations
        contained P. lactiflora,involving 673 ingredients. The main medicinal properties in Chinese patent medicines containing P.
        lactiflora were warm,followed by cold and neutral. The main medicinal flavor was sweet,followed by bitter and pungent. The
        main channel tropism was spleen,liver and heart channel. There were 165 kinds of main treatment diseases(menstrual disorder,
        dysmenorrhea,dizziness)and 159 main treatment syndromes(insufficiency of qi and blood,qi stagnation and blood stasis,liver
                                                            and kidney deficiency). Under the condition of 30% support
            Δ 基金项目:国家自然科学基金面上资助项目(No.81774264);国
        家中医药管理局区域中医(专科)诊疗中心建设项目[No.国中医药医                    degree and 0.9 confidence degree, there were 20 core
        政函〔2018〕205号];广州中医药大学一流学科研究重点项目(No.广中               combination  of  Chinese  patent  medicine  formulations
        医规划〔2018〕6号);邓氏岭南内科学派传承工作室项目(No.2015LP01)           containing P. lactiflora (Glycyrrhiza uralensis-P. lactiflora,
            *硕士研究生。研究方向:中医药防治脾胃系疾病。电话:                      Angelica sinensis-P. lactiflora,P. lactiflora-Poria cocos) and
        0769-86637993。E-mail:548640105@qq.com               19 association rules among drugs. Under the condition of 40%
            # 通信作者:教授,博士生导师。研究方向:中医药防治脾胃系疾
                                                            support degree and 0.9 confidence degree,there were 8 core
        病。电话:020-36591109。E-mail:liufb163@163.com

        ·2668  ·  China Pharmacy 2019 Vol. 30 No. 19                                中国药房    2019年第30卷第19期
   76   77   78   79   80   81   82   83   84   85   86